Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt No Debt
OPXA's Cash to Debt is ranked higher than
92% of the 831 Companies
in the Global Biotechnology industry.

( Industry Median: 56.93 vs. OPXA: No Debt )
Ranked among companies with meaningful Cash to Debt only.
OPXA' s 10-Year Cash to Debt Range
Min: 0   Max: No Debt
Current: No Debt

Equity to Asset 0.34
OPXA's Equity to Asset is ranked lower than
82% of the 598 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. OPXA: 0.34 )
Ranked among companies with meaningful Equity to Asset only.
OPXA' s 10-Year Equity to Asset Range
Min: -1246   Max: 0.78
Current: 0.34

-1246
0.78
F-Score: 3
Z-Score: -19.94
M-Score: -5.33
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -1135.36
OPXA's Operating margin (%) is ranked lower than
80% of the 650 Companies
in the Global Biotechnology industry.

( Industry Median: -76.18 vs. OPXA: -1135.36 )
Ranked among companies with meaningful Operating margin (%) only.
OPXA' s 10-Year Operating margin (%) Range
Min: -2950   Max: -12.65
Current: -1135.36

-2950
-12.65
Net-margin (%) -1133.51
OPXA's Net-margin (%) is ranked lower than
80% of the 650 Companies
in the Global Biotechnology industry.

( Industry Median: -72.15 vs. OPXA: -1133.51 )
Ranked among companies with meaningful Net-margin (%) only.
OPXA' s 10-Year Net-margin (%) Range
Min: -2200   Max: -6.13
Current: -1133.51

-2200
-6.13
ROE (%) -139.91
OPXA's ROE (%) is ranked lower than
88% of the 755 Companies
in the Global Biotechnology industry.

( Industry Median: -27.55 vs. OPXA: -139.91 )
Ranked among companies with meaningful ROE (%) only.
OPXA' s 10-Year ROE (%) Range
Min: -654.63   Max: -32.36
Current: -139.91

-654.63
-32.36
ROA (%) -91.67
OPXA's ROA (%) is ranked lower than
85% of the 834 Companies
in the Global Biotechnology industry.

( Industry Median: -23.43 vs. OPXA: -91.67 )
Ranked among companies with meaningful ROA (%) only.
OPXA' s 10-Year ROA (%) Range
Min: -8800   Max: -24.27
Current: -91.67

-8800
-24.27
ROC (Joel Greenblatt) (%) -1276.88
OPXA's ROC (Joel Greenblatt) (%) is ranked lower than
65% of the 806 Companies
in the Global Biotechnology industry.

( Industry Median: -358.68 vs. OPXA: -1276.88 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
OPXA' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -23600   Max: -410.49
Current: -1276.88

-23600
-410.49
EBITDA Growth (3Y)(%) -19.60
OPXA's EBITDA Growth (3Y)(%) is ranked lower than
69% of the 424 Companies
in the Global Biotechnology industry.

( Industry Median: -4.70 vs. OPXA: -19.60 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
OPXA' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -67.4   Max: 43.4
Current: -19.6

-67.4
43.4
EPS Growth (3Y)(%) -20.10
OPXA's EPS Growth (3Y)(%) is ranked lower than
67% of the 410 Companies
in the Global Biotechnology industry.

( Industry Median: -7.70 vs. OPXA: -20.10 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
OPXA' s 10-Year EPS Growth (3Y)(%) Range
Min: -64.4   Max: 49.6
Current: -20.1

-64.4
49.6
» OPXA's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Insider Trades

Latest Guru Trades with OPXA

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 4.50
OPXA's P/B is ranked higher than
68% of the 1029 Companies
in the Global Biotechnology industry.

( Industry Median: 4.50 vs. OPXA: 4.50 )
Ranked among companies with meaningful P/B only.
OPXA' s 10-Year P/B Range
Min: 1.88   Max: 11
Current: 4.5

1.88
11
P/S 12.70
OPXA's P/S is ranked higher than
66% of the 1029 Companies
in the Global Biotechnology industry.

( Industry Median: 12.17 vs. OPXA: 12.70 )
Ranked among companies with meaningful P/S only.
OPXA' s 10-Year P/S Range
Min: 9.45   Max: 78
Current: 12.7

9.45
78
Current Ratio 1.92
OPXA's Current Ratio is ranked lower than
75% of the 806 Companies
in the Global Biotechnology industry.

( Industry Median: 4.37 vs. OPXA: 1.92 )
Ranked among companies with meaningful Current Ratio only.
OPXA' s 10-Year Current Ratio Range
Min: 0.01   Max: 13.24
Current: 1.92

0.01
13.24
Quick Ratio 1.92
OPXA's Quick Ratio is ranked lower than
70% of the 806 Companies
in the Global Biotechnology industry.

( Industry Median: 4.16 vs. OPXA: 1.92 )
Ranked among companies with meaningful Quick Ratio only.
OPXA' s 10-Year Quick Ratio Range
Min: 0.01   Max: 13.24
Current: 1.92

0.01
13.24

Valuation & Return

vs
industry
vs
history
Price/Net Cash 8.70
OPXA's Price/Net Cash is ranked higher than
95% of the 816 Companies
in the Global Biotechnology industry.

( Industry Median: 14.50 vs. OPXA: 8.70 )
Ranked among companies with meaningful Price/Net Cash only.
OPXA' s 10-Year Price/Net Cash Range
Min: 1.31   Max: 193.94
Current: 8.7

1.31
193.94
Price/Net Current Asset Value 8.70
OPXA's Price/Net Current Asset Value is ranked higher than
95% of the 859 Companies
in the Global Biotechnology industry.

( Industry Median: 10.20 vs. OPXA: 8.70 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
OPXA' s 10-Year Price/Net Current Asset Value Range
Min: 1.21   Max: 109.97
Current: 8.7

1.21
109.97
Price/Tangible Book 4.70
OPXA's Price/Tangible Book is ranked higher than
93% of the 1028 Companies
in the Global Biotechnology industry.

( Industry Median: 6.50 vs. OPXA: 4.70 )
Ranked among companies with meaningful Price/Tangible Book only.
OPXA' s 10-Year Price/Tangible Book Range
Min: 1.58   Max: 7.59
Current: 4.7

1.58
7.59
Price/Median PS Value 0.70
OPXA's Price/Median PS Value is ranked higher than
92% of the 784 Companies
in the Global Biotechnology industry.

( Industry Median: 2.00 vs. OPXA: 0.70 )
Ranked among companies with meaningful Price/Median PS Value only.
OPXA' s 10-Year Price/Median PS Value Range
Min: 0.66   Max: 3.71
Current: 0.7

0.66
3.71
Earnings Yield (Greenblatt) -87.10
OPXA's Earnings Yield (Greenblatt) is ranked lower than
96% of the 1028 Companies
in the Global Biotechnology industry.

( Industry Median: -6.70 vs. OPXA: -87.10 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) only.
OPXA' s 10-Year Earnings Yield (Greenblatt) Range
Min: -2000   Max: 0
Current: -87.1

-2000
0

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:P6NN.Germany,
Opexa Therapeutics, Inc., formerly known as PharmaFrontiers Corp., was incorporated in Texas in March 1991. The Company's therapy is based on its proprietary T-cell technology. Opexa initiated a Phase IIb clinical trial of Tcelna in patients with secondary progressive multiple sclerosis. Tcelna has received Fast Track designation from the FDA in secondary progressive multiple sclerosis. Tcelna's combats the demyelination of the nerve fibers in the central nervous system, the underlying cause of multiple sclerosis. The Company faces competition from pharmaceutical and biotechnology companies, as well as numerous academic and research institutions and governmental agencies in the United States and abroad.
» More Articles for OPXA

Headlines

Articles On GuruFocus.com
Weekly CFO Buys Highlight Aug 19 2013 
Opexa Therapeutics Inc. Reports Operating Results (10-K) Mar 08 2011 
Opexa Therapeutics Inc. Reports Operating Results (10-Q) Nov 09 2010 
Opexa Therapeutics Inc. Reports Operating Results (10-Q) Aug 06 2010 
Opexa Therapeutics Inc. Reports Operating Results (10-Q) May 13 2010 
Opexa Therapeutics Inc. Reports Operating Results (10-Q) Nov 04 2009 
Opexa Therapeutics Reports Second Quarter 2009 Financial Results and Corporate Update Aug 13 2009 

More From Other Websites
Coverage initiated on Opexa Therapeutics by Maxim Group May 27 2015
OPEXA THERAPEUTICS, INC. Financials May 22 2015
Opexa Therapeutics to Present at the 2015 Marcum Microcap Conference May 21 2015
Opexa Therapeutics to Present at the 2015 Marcum Microcap Conference May 21 2015
10-Q for Opexa Therapeutics, Inc. May 14 2015
Opexa Therapeutics CEO Invited to Participate in Multiple May Conferences May 13 2015
Opexa Therapeutics CEO Invited to Participate in Multiple May Conferences May 13 2015
Opexa Therapeutics Reports First Quarter 2015 Financial Results and Provides Corporate Update May 12 2015
OPEXA THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition,... May 12 2015
Opexa Therapeutics Reports First Quarter 2015 Financial Results and Provides Corporate Update May 12 2015
Q1 2015 Opexa Therapeutics Inc Earnings Release - After Market Close May 12 2015
Opexa Therapeutics Announces News Release and Conference Call Schedule to Discuss First Quarter 2015... May 11 2015
Opexa Therapeutics Announces News Release and Conference Call Schedule to Discuss First Quarter 2015... May 11 2015
Opexa Therapeutics Invited to Present Biomarker Data from NMO Patients at The American Academy of... Apr 20 2015
Opexa Therapeutics Invited to Present Biomarker Data from NMO Patients at The American Academy of... Apr 20 2015
OPEXA THERAPEUTICS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits Apr 09 2015
Opexa Therapeutics, Inc. Announces Completion of Rights Offering Apr 09 2015
Opexa Therapeutics, Inc. Announces Completion of Rights Offering Apr 09 2015
Opexa Therapeutics Reminds Shareholders That Rights Offering Expires on April 8, 2015 at 5:00 PM ET Apr 06 2015
Opexa Therapeutics Reminds Shareholders That Rights Offering Expires on April 8, 2015 at 5:00 PM ET Apr 06 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK